

Data Sheet

Product Name: Omadacycline (hydrochloride)

Cat. No.: CS-6352


CAS No.: 1196800-39-1 **Molecular Formula:** C29H40N4O7.HCl

Molecular Weight: 593.11

Target: Bacterial

Pathway: Anti-infection

Solubility: H2O : ≥ 50 mg/mL (84.30 mM)



HCI

BIOLOGICAL ACTIVITY:

Omadacycline hydrochloride is novel, aminomethyl tetracycline antibiotic being developed for the treatment of community-acquired bacterial infections. The ED_{50} for Escherichia coli is 2.02 mg/kg. IC50 & Target: ED50: 2.02 mg/kg (Escherichia coli), 0.30-1.74 mg/kg (Staphylococcus aureus)^[1] In Vitro: The omadacycline MIC90s for MRSA, VRE, and beta-hemolytic streptococci are 1.0 μ g/mL, 0.25 μ g/mL, and 0.5 μ g/mL, respectively, and the omadacycline MIC90s for PRSP and H. influenzae are 0.25 μ g/ml and 2.0 μ g/mL, respectively. Omadacycline is active against organisms demonstrating the two major mechanisms of resistance, ribosomal protection and active tetracycline efflux^[1]. Omadacycline inhibits protein synthesis while having no significant effect on RNA, DNA and peptidoglycan synthesis. Further, omadacycline binds to the tetracycline binding site on the 30S subunit of the bacterial ribosome with enhanced binding similar to tigecycline based on additional molecular interactions^[2]. In Vivo: In vivo efficacy of omadacycline is demonstrated using an intraperitoneal infection model in mice. A single intravenous dose of omadacycline exhibits efficacy against Streptococcus pneumoniae, Escherichia coli, and Staphylococcus aureus, including tet (M) and tet (K) efflux-containing strains and MRSA strains. The 50% effective doses (ED₅₀s) for Streptococcus pneumoniae obtained ranged from 0.45 mg/kg to 3.39 mg/kg, the ED₅₀s for Staphylococcus aureus obtained ranges from 0.30 mg/kg to 1.74 mg/kg, and the ED₅₀ for Escherichia coli is 2.02 mg/kg^[1].

PROTOCOL (Extracted from published papers and Only for reference)

Animal Administration: Omadacycline is dissolved in sterile saline. [1] Mouse: Omadacycline is dissolved in sterile saline. Mice are infected using a 3-mL lock-top sterile syringe with a sterile 25-gauge, 5/8-in. needle. At 1 h postinfection (p.i.), mice are dosed intravenously (i.v.) with omadacycline or comparator compounds of interest at a volume of 10 ml/kg. A minimum of four dose levels are tested per experiment with 5 mice/group. The typical doses tested ranges from 0.11 to 18 mg/kg of body weight, with exceptions for comparators that requires significantly higher or lower doses to achieve 50% efficacy^[1].

References:

[1]. Macone AB, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58(2):1127-35.

[2]. Tanaka SK, et al. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem. 2016 Dec 15;24(24):6409-6419.

CAIndexNames:

2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-

Page 1 of 2 www.ChemScene.com



Page 2 of 2 www.ChemScene.com